Non-endoscopic Esophageal Sampling to Detect Barrett's Esophagus and Esophageal Cancer in Veterans
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study addresses prevention and early detection of esophageal adenocarcinoma (EAC). Prospectively collected Surveillance Epidemiology and End Results (SEER) data indicate that the incidence of esophageal adenocarcinoma (EAC) has increased more than 6-fold in the past four decades. The prognosis for patients with EAC is poor with less than 20% of patients surviving beyond 5 years. The veteran population is at increased risk for EAC and its precursor lesion, Barrett's esophagus (BE), due to increased prevalence of disease risk factors including advanced age, gastroesophageal reflux, caucasian race, male sex, smoking history, and obesity compared to the general population. Research has shown that veterans often present with an advanced cancer stage, despite opportunities to screen for BE in veterans with known risk factors. Therefore, there is an urgent clinical need to improve strategies for the detection and prevention of BE and EAC.
Currently, BE is diagnosed only when patients undergo endoscopy with esophagogastroduodenoscopy (EGD). However, due to the high cost of EGD and the lack of a randomized controlled trials supporting its efficacy, endoscopy to screen for BE is not routinely recommended. Current guidelines do recommend sedated EGD in patients with multiple BE risk factors, refractory GERD, or alarm symptoms. This strategy fails to detect BE in patients whose symptoms are well controlled with either over the counter medications or physician prescribed therapies. It also fails to detect BE in asymptomatic subjects who comprise 40% of those that develop EAC. Thus, less than 10% of esophageal adenocarcinomas are diagnosed as early stage lesions caught by surveillance of patients with previously detected BE. Ablative non-surgical therapies that have been developed for preventing cancer in patients with BE with high grade dysplasia over the past decade will have little impact and the 5 year survival for esophageal adenocarcinomas will remain a dismal 18% unless more effective programs for identifying BE and early EAC are developed.
The main hypothesis of this study is that incorporation of a non-endoscopic detection method in primary care practice will increase the positive predictive value of EGD and increase the detection of BE.
The objective of this study is to incorporate a novel unsedated BE screening method for veterans at risk for EAC into a primary care practice at a VA hospital.
Esocheck/Esoguard is a FDA approved device designed to sample the distal esophagus and analyze the collected material for presence of two methylated DNA markers.
The Specific Aims of this study are:
- To determine sensitivity, specificity, positive and negative predictive value of Esocheck/Esoguard performed in routine practice for detecting BE in an at risk Veteran population
- To compare the yield of detected BE using EGD alone vs. stepwise molecular diagnostics(Esocheck/Esoguard) and endoscopic screening strategy (EGD) in at risk Veteran population
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jeffrey Moore, PhD
- Phone Number: x45304 216-791-2300
- Email: jeffrey.moore5@va.gov
Study Contact Backup
- Name: Marcie Denallo, BS
- Phone Number: x45302 (216) 791-2300
- Email: marcie.denallo@va.gov
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44016
- Recruiting
- Louis Stokes Cleveland VA Medical Center
-
Contact:
- Katarina B Greer, MD
- Phone Number: 64057 216-791-3800
- Email: katarina.greer@va.gov
-
Contact:
- Andrew Blum, MD/PhD
- Phone Number: 216-368-2841
- Email: andrew.blum@va.gov
-
Sub-Investigator:
- Andrew E Blum, MD/PhD
-
Sub-Investigator:
- Ashley L Faulx, MD
-
Sub-Investigator:
- Amitabh Chak, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients who have symptomatic GERD and also meet criteria for upper endoscopic screening for BE will be accrued. Eligible patients will include:
- Adult Veterans > 40 and < 85 years old who have no prior EGD and can provide informed consent
- No known coagulopathy, no known esophageal varices.
- No significant dysphagia or odynophagia
- Documented GERD or use of proton pump inhibitors (PPIs) for > 5 years
- Meet ACG Clinical Guideline criteria for BE screening (that require presence of multiple risk factors 21). Eligible subjects to qualify must have will have GERD plus at least two additional risk factors for BE (white race, obesity defined as BMI > 30, male gender, smoking history, family history).
Exclusion Criteria:
- Patients with known coagulopathy (INR > 1.5) will be excluded
- Patients with known esophageal varices will be excluded.
- Patients with significant dysphagia (unable to swallow solids) or odynophagia will be excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Patients undergoing routine screening via upper endoscopy (EGD)
All enrolled patients will complete upper endoscopy for screening for Barrett's esophagus and esophageal adenocarcinoma.
|
All enrolled patients will complete the Esocheck screening test.
EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus.
The collected cell material is examined with a two marker panel combining methylated CCNA1 and VIM.
These methylated markers have 95% sensitivity and 91% specificity for detecting BE and EAC with an AUC=0.95 in studies performed among white men.
Diagnostic yield of this test among Veterans is unknown.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity and Specificity of Esocheck/Esoguard in a Veteran population
Time Frame: Through study completion, up to 2.5 years
|
The accuracy of a test which reports the presence or absence of a condition, in comparison to a 'Gold Standard'
|
Through study completion, up to 2.5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number/percentage of screened patients with diagnosis of Barrett's esophagus and/or esophageal adenocarcinoma
Time Frame: Through study completion, up to 2.5 years
|
Compare diagnostic yield of EGD to diagnostic yield of Esocheck/Esoguard in Veterans
|
Through study completion, up to 2.5 years
|
|
Cost of two screening strategies
Time Frame: Through study completion, up to 2.5 years
|
Compare the cost of screening all enrolled patients by EGD alone vs. cost of selective screening by EGD in patients who have had a positive Esocheck/Esoguard test
|
Through study completion, up to 2.5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Katarina B Greer, MD/MS, Louis Stokes Cleveland VA Medical Center
Publications and helpful links
General Publications
- Grady WM, Yu M, Markowitz SD, Chak A. Barrett's Esophagus and Esophageal Adenocarcinoma Biomarkers. Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2486-2494. doi: 10.1158/1055-9965.EPI-20-0223. Epub 2020 Oct 22.
- Kaz AM, Wong CJ, Luo Y, Virgin JB, Washington MK, Willis JE, Leidner RS, Chak A, Grady WM. DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Epigenetics. 2011 Dec;6(12):1403-12. doi: 10.4161/epi.6.12.18199.
- Moinova HR, LaFramboise T, Lutterbaugh JD, Chandar AK, Dumot J, Faulx A, Brock W, De la Cruz Cabrera O, Guda K, Barnholtz-Sloan JS, Iyer PG, Canto MI, Wang JS, Shaheen NJ, Thota PN, Willis JE, Chak A, Markowitz SD. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus. Sci Transl Med. 2018 Jan 17;10(424):eaao5848. doi: 10.1126/scitranslmed.aao5848.
- Tan WK, Sharma AN, Chak A, Fitzgerald RC. Progress in Screening for Barrett's Esophagus: Beyond Standard Upper Endoscopy. Gastrointest Endosc Clin N Am. 2021 Jan;31(1):43-58. doi: 10.1016/j.giec.2020.08.004.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1641950-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.